4d Molecular Therapeutics, INC. (FDMT) — 8-K Filings

All 8-K filings from 4d Molecular Therapeutics, INC.. Browse 20 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (20)

4D Molecular Therapeutics Files 8-K — Dec 10, 2025 Risk: medium
On December 10, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but provides no further specific details
4D Molecular Therapeutics Files 8-K on Board and Compensation Changes — Nov 17, 2025 Risk: low
On November 17, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing ind
4D Molecular Therapeutics Files 8-K on Financials — Nov 10, 2025 Risk: low
On November 10, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition, a
8-K Filing — Nov 7, 2025
4D Molecular Therapeutics Files 8-K — Nov 6, 2025 Risk: low
On November 6, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates information related to the company's results of operations and fi
4D Molecular Therapeutics Files 8-K — Oct 31, 2025 Risk: medium
On October 31, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement. Specific details o
4D Molecular Therapeutics Files 8-K with Board and Compensation Updates — Oct 2, 2025 Risk: low
On September 30, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements.
4D Molecular Therapeutics Files 8-K on Governance Changes — Jul 2, 2025 Risk: low
On June 27, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The f
4D Molecular Therapeutics Holds Annual Stockholder Meeting — Jun 20, 2025 Risk: low
On June 17, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report to announce the results of its annual meeting of stockholders. The company's stockholders
4D Molecular Therapeutics Files 8-K — Feb 28, 2025 Risk: low
On February 28, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condi
4D Molecular Therapeutics Files 8-K — Feb 10, 2025 Risk: low
On February 8, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of information. The company is
4D Molecular Therapeutics Files 8-K — Jan 10, 2025 Risk: low
On January 10, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates the company is involved in the biological products sector, specif
4D Molecular Therapeutics Reports Unregistered Equity Sale — Dec 11, 2024 Risk: medium
On December 6, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report detailing the unregistered sale of equity securities. The filing does not specify the n
4D Molecular Therapeutics Files 8-K Report — Sep 18, 2024 Risk: medium
On September 18, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Event' without specifying further details in the prov
4D Molecular Therapeutics Files 8-K — Jul 23, 2024 Risk: medium
On July 23, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning the company is releasing materia
4D Molecular Therapeutics Files 8-K Report — Jul 17, 2024 Risk: low
On July 17, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under 'Other Events'. No s
4D Molecular Therapeutics Files 8-K — Jun 7, 2024 Risk: medium
On June 7, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also inc
4D Molecular Therapeutics Holds Annual Stockholder Meeting — May 24, 2024 Risk: low
On May 21, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report indicating that it held its Annual Meeting of Stockholders. The primary purpose of the meet
4D Molecular Therapeutics Files Routine 8-K on Feb 6 Event — Feb 9, 2024 Risk: low
4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K on February 9, 2024, reporting an event that occurred on February 6, 2024. This filing is a routine update,
4D Molecular Therapeutics Reports Officer/Director Changes, Comp. Arrangements — Jan 4, 2024
4D Molecular Therapeutics, Inc. filed an 8-K on January 4, 2024, reporting an event that occurred on January 1, 2024, related to changes in directors or officer

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX